PDF(Pubmed)
Abstract：
Randomized controlled trials demonstrate a significant decline in hospital admissions and length of stay following the initiation of clozapine in individuals with bipolar disorder and schizophrenia, along with an increase in quality-adjusted life years. The morbidity and mortality associated with clozapine-induced gastrointestinal hypomotility (CIGH) is greater than agranulocytosis. Despite this, we only have clozapine risk evaluation and mitigation strategies by the US Food and Drug Administration for white cell count monitoring, but none exists for CIGH. Our case highlights CIGH due to multiple factors and recommendations to prevent it and enhance clozapine compliance by conducting a thorough literature review.
摘要：
随机对照试验表明，双相情感障碍和精神分裂症患者开始服用氯氮平后的住院人数和住院时间显着下降。随着质量调整寿命的增加。与氯氮平诱导的胃肠动力不足（CIGH）相关的发病率和死亡率高于粒细胞缺乏症。尽管如此,我们只有美国食品和药物管理局对氯氮平进行的白细胞计数监测风险评估和缓解策略，但没有一个人存在于CIGH。由于多种因素，我们的病例突出了sCIGH，并建议通过进行全面的文献综述来预防和提高氯氮平的依从性。
